August 22, 2020

New Zealand based soft tissue regeneration company Aroa Biosurgery Limited (Aroa) has gained further validation for Endoform?, its flagship extracellular matrix (ECM), with a new study published in the respected international peer-reviewed journal PLOS ONE.

The paper, titled ‘A novel chemotactic factor derived from the extracellular matrix protein decorin recruits mesenchymal stromal cells in vitro and in vivo’, stems from a collaborative study between the Aroa scientific team and scientists from Victoria University in Wellington, New Zealand and Charles River Laboratories in Germany. Aroa’s lead scientist for the study, Dr Sandi Dempsey, said the paper describes the ability of components found within the Endoform? ECM platform technology to signal stem cells in laboratory models.

Endoform? is derived from ovine (sheep) forestomach and includes a basement membrane layer and propria-submucosa (supportive connective tissue). It acts as a scaffold to grow new tissue lost or damaged through disease or injury, allowing the patient’s own cells to grow into the matrix to build new tissue and re-establish blood supply. As the patient continues to heal, this is replaced by their own tissue.

Aroa has five commercial products approved for sale in the US-based on the Endoform? technology, which have been used in more than four million procedures targeting chronic wounds, hernia, soft tissue, and breast reconstruction. Aroa has regulatory clearance in more than 37 countries and a deep patent portfolio.